Diabetic Macular Edema

A panel of retina specialists discuss how to balance durability, visual acuity, and other factors when selecting the appropriate regimen for patients with AMD and DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, share guidance on how to initiate conversations with patients who have been diagnosed with AMD or DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, review the clinical benefits of early detection of AMD and DME.

Carl D. Regillo, MD, FACS; Michael A. Klufas, MD; and David R. Lally, MD, discuss how increasing awareness regarding AMD and DME among patients and the medical community may lead to early treatment interventions.

However, initially observed eyes were found more at risk of developing moderate visual loss and more than 80% required treatment over 24 months.

The study shows fenofibrate use was associated with a lower risk of progression to PDR and VTDR, but not DME alone.

An increase in annual prevalence of beneficiaries with diabetes was observed in those who had ≥1 claim for DME (1.0% to 3.3%) and DME/VTDR (2.8% to 4.3%).

AGN-190584 showed superiority in efficacy over vehicle in mesopic DCNVA on day 30 with an acceptable safety profile for patients with presbyopia.

African American individuals and Hispanic individuals were more likely than non-Hispanic White individuals to report not being able to afford medications.

Pupillary dilation and manual eyelid lifting were shown to substantially increase visible retinal area and PLL-HMA detection using fully automated algorithms.

New findings observing links between visual acuity, disease progression and risk loci could inform new clinical studies of the leading cause of irreversible vision loss.

Monthly IV pegcetacoplan was associated with 39% reduced risk of progression from incomplete to complete RPE and outer retinal atrophy.

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

YOSEMITE and RHINE data further supports the novel agent for diabetic macular edema. A study investigators explains the impact of the new findings.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.

Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.

Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.

Key opinion leaders review the efficacy and safety of available VEGF inhibitors for the treatment of macular edema and explain how effectiveness is evaluated.

Experts in retinal diseases provide insight into when to prescribe VEGF inhibitors and the initial conversations with patients about treatment.

Proportion of eyes with IOP-related events supported monitoring in eyes treated with anti-VEGF therapy for macular edema associated with CRVO or HRVO for up to 60 months.

Phase 3 data show the solution works as fast 15 minutes and lasts for up to 6 hours, to improve near vision without impacting distance vision.